Media headlines about Organovo (NASDAQ:ONVO) have trended somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Organovo earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 44.8706211579219 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Average True Range – A Volatility Indicator – Organovo Holdings (NASDAQ: ONVO) (stocktradingdesk.com)
- Organovo Holdings, Inc. (ONVO) stock recent close stands at $0.95 (nasdaqfortune.com)
- Organovo Holdings, Inc. (NASDAQ:ONVO) – Will Shareholder Love To Invest in This Stock? (nasdaqjournal.com)
- Organovo Holdings, Inc. (ONVO) expected to achieve earnings growth of 8.20% for this year (wallstreetinvestorplace.com)
- Summary of what has been trade about Organovo Holdings, Inc. (ONVO) (wallstreetmorning.com)
Separately, Zacks Investment Research lowered Organovo from a “buy” rating to a “hold” rating in a research report on Saturday, February 17th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. Organovo presently has an average rating of “Hold” and a consensus target price of $3.40.
Organovo (NASDAQ:ONVO) last released its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. Organovo had a negative return on equity of 69.03% and a negative net margin of 881.93%. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $1.25 million. During the same period in the previous year, the company posted ($0.09) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. research analysts predict that Organovo will post -0.33 EPS for the current year.
Organovo Company Profile
Organovo Holdings, Inc is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.